Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 08:50:00 26/06/2024 pm IST 5-day change 1st Jan Change
1,007 DKK -2.04% Intraday chart for Novo Nordisk A/S +2.32% +44.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Sector Update: Health Care MT
European Equities Close Lower in Wednesday Trading MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected MT
Novo Nordisk: trial failure and impact on results CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial MT
Novo Nordisk makes impairment loss of $816 million in Q2 RE
AlphaValue/Baader Europe Downgrades Novo Nordisk to Add from Buy, Raises PT MT
China Approves Novo Nordisk's Injection for Long-term Weight Management MT
Health Care Up as Novo Nordisk Gets China OK -- Health Care Roundup DJ
Trending : Novo Nordisk's Wegovy Weight-Loss Drug Gets Chinese Approval DJ
Sector Update: Health Care Stocks Easing Tuesday Afternoon MT
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls MT
European Equities Close Lower in Tuesday Trading; EC Accuses Microsoft of Breaking Antitrust Laws MT
MEDIA-Novo weight-loss drug Saxenda poses risk to bone health, study finds - Bloomberg News RE
Market Update-Europe closes lower in a session marked by a wait-and-see attitude RE
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading MT
Novo Nordisk Wins Weight-Loss Drug Approval in China; Plans $4.1 Billion US Facility MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla... Our Logo
Sector Update: Health Care Stocks Advance Pre-Bell Tuesday MT
Sector Update: Health Care MT
Exchange-Traded Funds Edge Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Upcoming Economic Reports MT
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028 DKK
Average target price
938.1 DKK
Spread / Average Target
-8.74%
Consensus